Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376877 | 0.90 | MCHR1 (0.50) | MCHR1HTR6ASIC3 | |
| SCHEMBL5376117 | 0.84 | PTGS1 (0.42) | HTR6PTGDR2PTGS1PTGS2 | |
| SCHEMBL5372839 | 0.82 | PTGS1 (0.42) | MCHR1HTR6PTGS1PTGS2 | |
| SCHEMBL5376070 | 0.81 | HTR2A (0.44) | MCHR1HTR6PTGS1PTGS2 | |
| SCHEMBL5371664 | 0.78 | PTGS1 (0.63) | MCHR1HTR6PTGDR2PTGS1PTGS2 | |
| SCHEMBL5373439 | 0.78 | HTR6 (0.58) | HTR6PTGS1PTGS2 | |
| SCHEMBL5375896 | 0.76 | HTR6 (0.41) | MCHR1HTR6PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL3096737 | 0.74 | PTGDR2 (0.58) | HTR6PTGDR2PTGS1PTGS2PTGDR | |
| SCHEMBL5376849 | 0.73 | MCHR1 (0.47) | MCHR1HTR6 | |
| SCHEMBL6628574 | 0.70 | PTGS1 (0.46) | MCHR1HTR6PTGS1PTGS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MCHR1 4604/4885HTR6 2138/4885PTGDR2 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.